Overall, there is no good quality evidence that cabergoline or other dopamine agonists are of benefit in patients with PCOS undergoing ovarian stimulation in GnRH antagonist protocols with an agonist trigger, however in contexts where these treatment options are not possible, administration of an oral dopamine agonist from the time of hCG trigger or oocyte collection can reduce moderate-to-severe OHSS. Here, GNRH1 is linked to ovarian hyperstimulation syndrome.